Source: Business Wire

Press Release: Stimit : STIMIT is Enrolling Patients in Clinical Trial of Noninvasive Diaphragm Neurostimulation Device - Pioneering a Transformation in Ventilation and Critical Care

BIEL, Switzerland--(BUSINESS WIRE)-- #ClinicalTrials--STIMIT AG announced today it is enrolling patients in its FDA Investigational Device Exemption (IDE) clinical trial, "STIMIT ACTIVATOR 1 PIVOTAL STUDY," with world renowned clinical centers. STIMIT's initial therapy in its platform uses noninvasive diaphragm neurostimulation and is designed to preserve diaphragm thickness in patients who are on invasive mechanical ventilation (MV) and thus are at risk of diaphragmatic dysfunction/atrophy. The IDE study will e

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
1-25
Ronja Muller Bruhn's photo - Co-Founder & CEO of Stimit

Co-Founder & CEO

Ronja Muller Bruhn

CEO Approval Rating

90/100

Read more